Myovant Spurns Sumitovant Offer, Remains Open To Higher-Value Deal
Sumitomo Pharma Subsidiary Already Owns 52%
Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies.
